Cargando…
HER2-PI9 and HER2-I12: two novel and functionally active splice variants of the oncogene HER2 in breast cancer
In this study, two novel alternative splice variants of HER2, named HER2-PI9 and HER2-I12, were identified in breast cancer cell lines and breast tumour tissues. Whilst HER2-P19 arises from the inclusion of an 117 bp cassette-exon of intron 9 of HER2, HER2-I12 results from intron 12 inclusion. In si...
Autores principales: | Hart, Vic, Silipo, Marco, Satam, Swapna, Gautrey, Hannah, Kirby, John, Tyson-Capper, Alison |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8397700/ https://www.ncbi.nlm.nih.gov/pubmed/34136934 http://dx.doi.org/10.1007/s00432-021-03689-1 |
Ejemplares similares
-
HER2 splice variants in breast cancer: investigating their impact on diagnosis and treatment outcomes
por: Hart, Vic, et al.
Publicado: (2020) -
Clinical Significance of HER-2 Splice Variants in Breast Cancer Progression and Drug Resistance
por: Jackson, Claire, et al.
Publicado: (2013) -
Targeting of the HER2/HER3 signaling axis overcomes ligand‐mediated resistance to trastuzumab in HER2‐positive breast cancer
por: Watanabe, Satomi, et al.
Publicado: (2019) -
Using the HER2/CEP17 FISH Ratio to Predict Pathologic Complete Response Following Neoadjuvant Anti-HER2 Doublet Therapy in HER2+ Breast Cancer
por: Lander, Eric M, et al.
Publicado: (2022) -
Mutant HER2 needs mutant HER3 to be an effective oncogene
por: Trenker, Raphael, et al.
Publicado: (2021)